To this end, we demonstrated that YAP inhibition, using either a pharmacological compound (VP) or siRNA-mediated knockdown, reduces LOX expression in AT2 cells in vitro, experimental lung fibrosis in vivo, and human lung fibrosis modeled in PCLS ex vivo. Here, YAP1 is linked to pulmonary fibrosis.